Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 23763709)

1.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.

Shah HH, Fishbane SN.

Semin Dial. 2013 Sep-Oct;26(5):543-5. doi: 10.1111/sdi.12108. Epub 2013 Jun 14. Review. No abstract available.

PMID:
23763709
2.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?

Kovesdy CP.

Semin Dial. 2013 Sep-Oct;26(5):540-2. doi: 10.1111/sdi.12107. Epub 2013 Jun 5. No abstract available.

PMID:
23734775
3.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.

Battistella M, Chan CT.

Semin Dial. 2013 Sep-Oct;26(5):537-40. doi: 10.1111/sdi.12106. Epub 2013 Jun 5. Review. No abstract available.

PMID:
23734745
4.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.

Singh AK.

Semin Dial. 2013 Sep-Oct;26(5):531-4. doi: 10.1111/sdi.12104. Epub 2013 Jun 14. No abstract available.

PMID:
23763643
5.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis.

Shirazian S, Grant C, Miller I, Fishbane S.

Semin Dial. 2013 Sep-Oct;26(5):534-6. doi: 10.1111/sdi.12105. Epub 2013 Jun 14. Review. No abstract available.

PMID:
23763675
6.

[Current issues in erythropoietin therapy of renal anemia].

Zakar G.

Lege Artis Med. 2007 Oct;17(10):667-73. Review. Hungarian.

PMID:
19227596
7.

A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.

Hörbrand F, Bramlage P, Fischaleck J, Hasford J, Brunkhorst R.

Eur J Clin Pharmacol. 2013 Apr;69(4):929-36. doi: 10.1007/s00228-012-1412-5. Epub 2012 Oct 2.

PMID:
23052412
8.

Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.

Molina M, Navarro MJ, de Gracia C, Alvarez G, de Alarcon R, Garcia MA.

Ren Fail. 2008;30(8):778-83. doi: 10.1080/08860220802248977.

PMID:
18791951
9.
10.

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.

Besarab A, Zeig SN, Martin ER, Pergola PE, Whittier FC, Zabaneh RI, Schiller B, Mayo M, Francisco CA, Polu KR, Duliege AM.

BMC Nephrol. 2012 Aug 30;13:95. doi: 10.1186/1471-2369-13-95.

11.

Anemia treatment in patients with chronic kidney disease.

Drüeke TB.

N Engl J Med. 2013 Jan 24;368(4):387-9. doi: 10.1056/NEJMe1215043. No abstract available.

PMID:
23343068
12.

On peginesatide and anemia treatment in CKD.

Parfrey PS, Warden G, Barrett BJ.

Am J Kidney Dis. 2013 Oct;62(4):659-61. doi: 10.1053/j.ajkd.2013.05.008. Epub 2013 Jun 28. No abstract available.

PMID:
23810692
13.

The new label for erythropoiesis stimulating agents: the FDA'S sentence.

Fishbane S, Jhaveri KD.

Semin Dial. 2012 May;25(3):263-6. doi: 10.1111/j.1525-139X.2012.01065.x. Epub 2012 Apr 20.

PMID:
22515844
14.

Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.

Raymond CB, Wazny LD, Vercaigne LM, Lesperance EM, Skwarchuk DE, Bernstein KN.

CANNT J. 2008 Jan-Mar;18(1):39-43.

PMID:
18435363
15.

Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.

Agarwal AK.

Expert Opin Drug Saf. 2009 Mar;8(2):145-53. doi: 10.1517/14740330902793031 . Review.

PMID:
19309243
16.

Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI.

J Natl Cancer Inst. 2009 Dec 2;101(23):1633-41. doi: 10.1093/jnci/djp387. Epub 2009 Nov 10. Erratum in: J Natl Cancer Inst. 2010 Feb 24;102(4):282-3.

17.

[Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].

Pérez-García R, Rodríguez Benítez P, Jofre R, López-Gómez JM, Villaverde MT, Blanco A, Blanco S, Sánchez M.

Nefrologia. 2007;27(3):340-9. Spanish.

18.

[Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].

Nagano N.

Nihon Yakurigaku Zasshi. 2008 Apr;131(4):291-9. Review. Japanese. No abstract available.

PMID:
18408341
19.

[Anemia in chronic renal failure. The role of L-carnitine in the treatment of anemia of hemodialyzed patients].

Wanic-Kossowska M, Kurzawska-Firlej D, Kaźmierski M, Czekalski S.

Pol Arch Med Wewn. 2003 Jan;109(1):105-11. Review. Polish. No abstract available.

PMID:
12879773
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk